Man Group plc Takes $940,000 Position in Xencor, Inc. $XNCR

Man Group plc purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR) in the second quarter, HoldingsChannel.com reports. The firm purchased 58,380 shares of the biopharmaceutical company’s stock, valued at approximately $940,000.

A number of other institutional investors have also recently added to or reduced their stakes in XNCR. AQR Capital Management LLC acquired a new stake in shares of Xencor during the first quarter valued at about $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Xencor by 9.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Xencor by 89.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after purchasing an additional 344,088 shares in the last quarter. Creative Planning grew its stake in Xencor by 25.3% during the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,661 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Xencor by 170.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock worth $2,594,000 after purchasing an additional 208,182 shares during the last quarter.

Xencor Trading Down 1.0%

Shares of NASDAQ XNCR opened at $26.62 on Friday. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -12.27 and a beta of 0.88. Xencor, Inc. has a twelve month low of $8.05 and a twelve month high of $30.61. The business has a 50 day simple moving average of $20.83 and a 200-day simple moving average of $15.22.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period last year, the business posted ($0.41) earnings per share. As a group, equities analysts predict that Xencor, Inc. will post -3 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on XNCR shares. Raymond James Financial increased their target price on Xencor from $40.00 to $46.00 and gave the company a “strong-buy” rating in a research note on Tuesday. Cantor Fitzgerald upped their price target on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of Xencor from $14.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday. Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Wedbush upped their target price on shares of Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average target price of $30.71.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.